Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
ADAP logo ADAP
Upturn stock ratingUpturn stock rating
ADAP logo

Adaptimmune Therapeutics Plc (ADAP)

Upturn stock ratingUpturn stock rating
$0.26
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

04/22/2025: ADAP (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

9 Analysts rated it

These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.

Year Target Price $1.58

Year Target Price $1.58

Analyst’s Price TargetsFor last 52 week
$1.58Target price
Low$0.2
Current$0.26
high$1.48

Analysis of Past Performance

Type Stock
Historic Profit -13.45%
Avg. Invested days 34
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 04/22/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 64.94M USD
Price to earnings Ratio -
1Y Target Price 1.45
Price to earnings Ratio -
1Y Target Price 1.45
Volume (30-day avg) -
Beta 2.25
52 Weeks Range 0.20 - 1.48
Updated Date 06/29/2025
52 Weeks Range 0.20 - 1.48
Updated Date 06/29/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.3

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -38.91%
Operating Margin (TTM) -604.96%

Management Effectiveness

Return on Assets (TTM) -14.19%
Return on Equity (TTM) -275.74%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 52940917
Price to Sales(TTM) 0.36
Enterprise Value 52940917
Price to Sales(TTM) 0.36
Enterprise Value to Revenue 0.29
Enterprise Value to EBITDA -1.71
Shares Outstanding 265052000
Shares Floating 1046757646
Shares Outstanding 265052000
Shares Floating 1046757646
Percent Insiders 0.63
Percent Institutions 44.16

Analyst Ratings

Rating 3.78
Target Price 1.58
Buy 2
Strong Buy 3
Buy 2
Strong Buy 3
Hold 3
Sell 1
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Adaptimmune Therapeutics Plc

stock logo

Company Overview

overview logo History and Background

Adaptimmune Therapeutics Plc, founded in 2008, focuses on developing T-cell therapies for cancer. It originated from research at Oxford University. Significant milestones include clinical trial advancements and regulatory approvals in 2024.

business area logo Core Business Areas

  • T-cell Therapy Development: Develops engineered T-cell therapies (TCR T-cells) designed to target and destroy cancer cells.
  • Clinical Trials: Conducts clinical trials to evaluate the safety and efficacy of its T-cell therapies across various cancer types.
  • Manufacturing and Supply: Focuses on the manufacturing and supply of its T-cell therapy products to support clinical trials and commercialization.

leadership logo Leadership and Structure

The leadership team comprises experienced executives in the biotechnology industry. The organizational structure is focused on research and development, clinical operations, and commercialization.

Top Products and Market Share

overview logo Key Offerings

  • Afami-cel (Afamitresgene autoleucel) (TCR T-cell therapy for synovial sarcoma): FDA-approved treatment for advanced synovial sarcoma. Competitors include conventional chemotherapy and radiation therapies, as well as other emerging immunotherapies, cell therapies and TIL (tumor-infiltrating lymphocyte) therapies from companies like Iovance. No definitive market share data is currently available, as it is a new therapy.

Market Dynamics

industry overview logo Industry Overview

The immunotherapy market is experiencing significant growth, driven by advancements in cancer treatment and a growing demand for personalized therapies.

Positioning

Adaptimmune is a key player in the TCR T-cell therapy field, specializing in targeting solid tumors. Its competitive advantage lies in its proprietary TCR engineering platform.

Total Addressable Market (TAM)

The TAM for cancer immunotherapy is estimated at billions of dollars annually. Adaptimmune is positioned to capture a portion of this market through its novel T-cell therapies.

Upturn SWOT Analysis

Strengths

  • Proprietary TCR engineering platform
  • FDA approval for Afami-cel (TCR T-cell therapy for synovial sarcoma)
  • Strong research and development capabilities
  • Experienced management team

Weaknesses

  • High research and development costs
  • Dependence on regulatory approvals
  • Limited number of approved products
  • Manufacturing complexity

Opportunities

  • Expansion of T-cell therapy pipeline to other cancer types
  • Partnerships with pharmaceutical companies
  • Advancements in TCR engineering technology
  • Increasing demand for personalized cancer therapies

Threats

  • Competition from other immunotherapy companies
  • Regulatory hurdles
  • Clinical trial failures
  • Patent disputes

Competitors and Market Share

competitor logo Key Competitors

  • IOVA
  • NK
  • CRSP

Competitive Landscape

Adaptimmune has a focused approach with their engineered T cell receptor while other companies take different novel approaches to cancer treatments. Adaptimmune's is focused on solid tumors.

Growth Trajectory and Initiatives

Historical Growth: Focus on clinical trial results and securing FDA approval.

Future Projections: Projected growth is driven by commercialization of approved products and expansion of the pipeline. Analyst estimates will need to be accessed to input the numerical projections.

Recent Initiatives: Initiatives focused on expanding clinical trials and seeking regulatory approvals for new indications.

Summary

Adaptimmune Therapeutics Plc is focused on T-cell therapies for cancer. The company recently acquired FDA approval for its lead TCR T-cell therapy, Afami-cel. However, it also faces challenges related to high R&D costs and competition. Future success depends on expanding its product pipeline and commercializing the current treatments and other new novel therapies.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Website
  • SEC Filings
  • Analyst Reports
  • FDA Website

Disclaimers:

The information provided is for informational purposes only and should not be considered financial advice. Market share estimates are approximate and based on available data. Consult with a financial professional before making any investment decisions.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Adaptimmune Therapeutics Plc

Exchange NASDAQ
Headquaters -
IPO Launch date 2015-05-06
CEO & Director Mr. Adrian G. Rawcliffe
Sector Healthcare
Industry Biotechnology
Full time employees 506
Full time employees 506

Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops TECELRA ((famitresgene autoleucel or afami-cel), a genetically modified autologous T-cell immunotherapy for the treatment of adults with unresectable or metastatic synovial sarcoma; Lete-cel for the treatment synovial sarcoma and myxoid liposarcoma; and ADP-5701, which is in Phase 1 clinical trial for the treatment of head and neck cancer. The company also focuses on the development of T-cell therapies directed to PRAME (ADP-600) and CD70 (ADP-520). It has strategic collaboration with Galapagos to clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel produced on Galapagos' decentralized manufacturing platform (ADP-5701) in patients with head and neck cancer; collaboration and license agreement with Noile-Immune Biotech, Inc. and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.